FDA weighs loosening rules on unproven peptide injections

The FDA says it will convene a July advisory panel to decide whether seven popular but unproven peptide injections should be added to a list allowing pharmaceutical compounding, potentially easing restrictions. The move aligns with Health Secretary RFK Jr.’s push to loosen peptide regulations and the stance of MAHA supporters, though critics warn that most peptides lack safety data and could bypass traditional drug testing. Even if advisers approve, the agency must still complete formal rulemaking. Some peptides are banned by sports bodies and have previously been placed on restricted lists due to health risks, underscoring ongoing safety concerns around this market.